Benzatropine Injection 2mg/2ml Vial

Benzatropine Injection 2mg/2ml Vial

Benzatropine Injection, supplied in a 2mg/2ml vial, is a synthetic anticholinergic agent that is used primarily for its antimuscarinic effects. It is commonly employed in the management of Parkinsonian syndromes and the control of extrapyramidal disorders due to neuroleptic drugs, except tardive dyskinesia.

Product Specifications:
- Concentration: 2mg of Benzatropine Mesylate per 2ml
- Formulation: Aqueous, sterile solution for intravenous or intramuscular injection
- Packaging: Single-dose vial to ensure safety and sterility
- Storage: Store between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)

Common Applications:
- Management of Parkinson's disease symptoms
- Treatment of drug-induced extrapyramidal reactions
- Utilized by neurologists, psychiatrists, and primary care physicians

User Groups:
- Patients diagnosed with Parkinson's disease
- Individuals experiencing extrapyramidal side effects from antipsychotic medications

Overview of Phebra:
Phebra is an established pharmaceutical company that specializes in the development and manufacturing of niche injectable and oral products for critical care and hospital use. With a commitment to quality and patient safety, Phebra has positioned itself as an authority in the field of neurology and psychiatry medication. Their rigorous quality control measures and dedication to research and development make them a trusted supplier of Benzatropine Injection and other specialized pharmaceuticals. Phebra's expertise in the product category of anticholinergic agents is reflected in their meticulous production processes and their adherence to stringent regulatory standards, ensuring that healthcare professionals and patients receive effective and reliable medications.